APO Research
Talk to an analyst

APO RESEARCH · REPORT

Amyotrophic Lateral Sclerosis (ALS) Treatment

Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die.

The cause is not known in 90% to 95% of cases. The remaining 5–10% of cases are inherited from a person's parents. About half of these genetic cases are due to one of two specific genes. The underlying mechanism involves damage to both upper and lower motor neurons. The diagnosis is based on a person's signs and symptoms, with testing done to rule out other potential causes.

Selected research

Industry Growth & Trends

Global Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Growth and Trends Forecast to 2032

21 December 202587 pages

Choose your research edition.

Industry ResearchAmyotrophic Lateral Sclerosis (ALS) Treatment Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Growth and Trends Forecast to 203287 pages · $3,450 USDMarket StructureGlobal Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032189 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Amyotrophic Lateral Sclerosis (ALS) Treatment Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Amyotrophic Lateral Sclerosis (ALS) Treatment Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die.

The cause is not known in 90% to 95% of cases. The remaining 5–10% of cases are inherited from a person's parents. About half of these genetic cases are due to one of two specific genes. The underlying mechanism involves damage to both upper and lower motor neurons. The diagnosis is based on a person's signs and symptoms, with testing done to rule out other potential causes.

According to APO Research, the global Amyotrophic Lateral Sclerosis (ALS) Treatment market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

Read the full market overview

Report Scope

This report provides a structured, data-driven view of the global Amyotrophic Lateral Sclerosis (ALS) Treatment market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Amyotrophic Lateral Sclerosis (ALS) Treatment market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Amyotrophic Lateral Sclerosis (ALS) Treatment market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Amyotrophic Lateral Sclerosis (ALS) Treatment.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Amyotrophic Lateral Sclerosis (ALS) Treatment market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Company

Mitsubishi Tanabe Pharma

Sanofi

Mylan Pharma

Apotex

Glemark Generics

Covis Pharma

Sun Pharma

Lunan Pharma

Amyotrophic Lateral Sclerosis (ALS) Treatment Segment by Type

Riluzole

Edaravone (Radicava)

Other

Amyotrophic Lateral Sclerosis (ALS) Treatment Segment by Application

Hospital

Drugs Store

Other

Amyotrophic Lateral Sclerosis (ALS) Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Amyotrophic Lateral Sclerosis (ALS) Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Amyotrophic Lateral Sclerosis (ALS) Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Amyotrophic Lateral Sclerosis (ALS) Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Amyotrophic Lateral Sclerosis (ALS) Treatment companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Region (2021-2026) Table 4. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Region (2027-2032) Table 6. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2021-2026) & (US$ Million) Table 8. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Share by Type (2021-2026) Table 9. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Share Forecasted by Type (2027-2032) Table 11. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2021-2026) & (US$ Million) Table 23. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Share by Application (2021-2026) Table 24. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Share Forecasted by Application (2027-2032) Table 26. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Trends Table 37. Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Drivers Table 38. Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Opportunities and Challenges Table 39. Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Restraints Table 40. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Company (2021-2026) Table 42. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Key Company Headquarters & Area Served Table 44. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Company, Product Type & Application Table 45. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Amyotrophic Lateral Sclerosis (ALS) Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. Mitsubishi Tanabe Pharma Company Information Table 49. Mitsubishi Tanabe Pharma Business Overview Table 50. Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio Table 52. Mitsubishi Tanabe Pharma Recent Development Table 53. Sanofi Company Information Table 54. Sanofi Business Overview Table 55. Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio Table 57. Sanofi Recent Development Table 58. Mylan Pharma Company Information Table 59. Mylan Pharma Business Overview Table 60. Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio Table 62. Mylan Pharma Recent Development Table 63. Apotex Company Information Table 64. Apotex Business Overview Table 65. Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio Table 67. Apotex Recent Development Table 68. Glemark Generics Company Information Table 69. Glemark Generics Business Overview Table 70. Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio Table 72. Glemark Generics Recent Development Table 73. Covis Pharma Company Information Table 74. Covis Pharma Business Overview Table 75. Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio Table 77. Covis Pharma Recent Development Table 78. Sun Pharma Company Information Table 79. Sun Pharma Business Overview Table 80. Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio Table 82. Sun Pharma Recent Development Table 83. Lunan Pharma Company Information Table 84. Lunan Pharma Business Overview Table 85. Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio Table 87. Lunan Pharma Recent Development Table 88. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 89. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2021-2026) & (US$ Million) Table 90. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Country (2021-2026) Table 91. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 92. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share Forecast by Country (2027-2032) Table 93. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 94. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2021-2026) & (US$ Million) Table 95. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Country (2021-2026) Table 96. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 97. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share Forecast by Country (2027-2032) Table 98. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 99. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2021-2026) & (US$ Million) Table 100. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Country (2021-2026) Table 101. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 102. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share Forecast by Country (2027-2032) Table 103. Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 104. Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2021-2026) & (US$ Million) Table 105. Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Country (2021-2026) Table 106. Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 107. Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share Forecast by Country (2027-2032) Table 108. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 109. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2021-2026) & (US$ Million) Table 110. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Country (2021-2026) Table 111. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Forecast by Country (2027-2032) & (US$ Million) Table 112. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share Forecast by Country (2027-2032) Table 113. Research Programs/Design for This Report Table 114. Authors List of This Report Table 115. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Amyotrophic Lateral Sclerosis (ALS) Treatment Product Image Figure 3. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2021-2032) & (US$ Million) Figure 5. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Region: 2025 VS 2032 Figure 6. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Region (2021-2032) Figure 7. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. Riluzole Image Figure 13. Global Riluzole Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. Edaravone (Radicava) Image Figure 15. Global Edaravone (Radicava) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Other Image Figure 17. Global Other Market Size YoY Growth (2021-2032) & (US$ Million) Figure 18. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Overview by Type (2021-2032) & (US$ Million) Figure 19. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Type 2025 VS 2032 Figure 20. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Share by Type (2021-2032) Figure 21. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Share by Type (2021-2032) Figure 22. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Share by Type (2021-2032) Figure 23. Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Share by Type (2021-2032) Figure 24. Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Share by Type (2021-2032) Figure 25. Hospital Image Figure 26. Global Hospital Market Size YoY Growth (2021-2032) & (US$ Million) Figure 27. Drugs Store Image Figure 28. Global Drugs Store Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. Other Image Figure 30. Global Other Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Overview by Application (2021-2032) & (US$ Million) Figure 32. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Application 2025 VS 2032 Figure 33. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Share by Application (2021-2032) Figure 34. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Share by Application (2021-2032) Figure 35. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Share by Application (2021-2032) Figure 36. Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Share by Application (2021-2032) Figure 37. Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Share by Application (2021-2032) Figure 38. Global Top 5 and 10 Amyotrophic Lateral Sclerosis (ALS) Treatment Players Market Share by Revenue in 2025 Figure 39. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 40. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 41. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 42. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Country (2021-2032) Figure 43. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Country (2021-2032) Figure 46. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 47. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 48. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Country (2021-2032) Figure 49. Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Country (2021-2032) Figure 52. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 53. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Country: 2021 VS 2025 VS 2032 Figure 54. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Country (2021-2032) Figure 55. Years Considered Figure 56. Research Process Figure 57. Key Executives Interviewed

Scope & coverage.

Types
  • Riluzole
  • Edaravone (Radicava)
  • Other
Applications
  • Hospital
  • Drugs Store
  • Other
Companies covered
  • Mitsubishi Tanabe Pharma
  • Sanofi
  • Mylan Pharma
  • Apotex
  • Glemark Generics
  • Covis Pharma
  • Sun Pharma
  • Lunan Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Region (2021-2032)
  5. 1.4.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Region (2021-2026)
  6. 1.4.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Region (2027-2032)
  7. 1.5 Key Regions Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2021-2032)
  8. 1.5.1 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth Rate (2021-2032)
2 Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 Riluzole
  3. 2.1.2 Edaravone (Radicava)
  4. 2.1.3 Other
  5. 2.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type
  6. 2.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Overview by Type (2021-2032)
  7. 2.2.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Historic Market Size Review by Type (2021-2026)
  8. 2.2.3 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Forecasted by Type (2027-2032)
  9. 2.3 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Regions
  10. 2.3.1 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Breakdown by Type (2021-2026)
  11. 2.3.2 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Breakdown by Type (2021-2026)
  12. 2.3.3 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Breakdown by Type (2021-2026)
  13. 2.3.4 South America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Breakdown by Type (2021-2026)
  14. 2.3.5 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Breakdown by Type (2021-2026)
3 Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 Hospital
  3. 3.1.2 Drugs Store
  4. 3.1.3 Other
  5. 3.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application
  6. 3.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Overview by Application (2021-2032)
  7. 3.2.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Historic Market Size Review by Application (2021-2026)
  8. 3.2.3 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Forecasted by Application (2027-2032)
  9. 3.3 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Regions
  10. 3.3.1 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Breakdown by Application (2021-2026)
  11. 3.3.2 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Breakdown by Application (2021-2026)
  12. 3.3.3 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Breakdown by Application (2021-2026)
  13. 3.3.4 South America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Breakdown by Application (2021-2026)
  14. 3.3.5 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Trends
  2. 4.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Drivers
  3. 4.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Opportunities and Challenges
  4. 4.4 Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (2021-2026)
  2. 5.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Key Company Headquarters & Area Served
  4. 5.4 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Company, Product Type & Application
  5. 5.5 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Amyotrophic Lateral Sclerosis (ALS) Treatment Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Amyotrophic Lateral Sclerosis (ALS) Treatment Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 Mitsubishi Tanabe Pharma
  2. 6.1.1 Mitsubishi Tanabe Pharma Company Information
  3. 6.1.2 Mitsubishi Tanabe Pharma Business Overview
  4. 6.1.3 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio
  6. 6.1.5 Mitsubishi Tanabe Pharma Recent Developments
  7. 6.2 Sanofi
  8. 6.2.1 Sanofi Company Information
  9. 6.2.2 Sanofi Business Overview
  10. 6.2.3 Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio
  12. 6.2.5 Sanofi Recent Developments
  13. 6.3 Mylan Pharma
  14. 6.3.1 Mylan Pharma Company Information
  15. 6.3.2 Mylan Pharma Business Overview
  16. 6.3.3 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio
  18. 6.3.5 Mylan Pharma Recent Developments
  19. 6.4 Apotex
  20. 6.4.1 Apotex Company Information
  21. 6.4.2 Apotex Business Overview
  22. 6.4.3 Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio
  24. 6.4.5 Apotex Recent Developments
  25. 6.5 Glemark Generics
  26. 6.5.1 Glemark Generics Company Information
  27. 6.5.2 Glemark Generics Business Overview
  28. 6.5.3 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio
  30. 6.5.5 Glemark Generics Recent Developments
  31. 6.6 Covis Pharma
  32. 6.6.1 Covis Pharma Company Information
  33. 6.6.2 Covis Pharma Business Overview
  34. 6.6.3 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio
  36. 6.6.5 Covis Pharma Recent Developments
  37. 6.7 Sun Pharma
  38. 6.7.1 Sun Pharma Company Information
  39. 6.7.2 Sun Pharma Business Overview
  40. 6.7.3 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio
  42. 6.7.5 Sun Pharma Recent Developments
  43. 6.8 Lunan Pharma
  44. 6.8.1 Lunan Pharma Company Information
  45. 6.8.2 Lunan Pharma Business Overview
  46. 6.8.3 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio
  48. 6.8.5 Lunan Pharma Recent Developments
7 North America
  1. 7.1 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2021-2026)
  3. 7.3 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2021-2026)
  3. 8.3 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2021-2026)
  3. 10.3 South America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst